The 26th JFCR-ISCC

December 7-8, 2022
Miraikan - The National Museum of Emerging Science and Innovation 7F
2-3-6, Aomi, Koto-ku, Tokyo, Japan

December 7

12:00-

Poster viewing

12:00-12:30

Committee meeting

Opening Remark

12:50-13:00

Naoya Fujita (JFCR, Tokyo)

Opening remark

Poster Flash Talks

Chairperson: Manabu Kawada (Inst. Microbial Chem., Tokyo)

13:00-13:50

Toshihiro Shibutani (Taiho Pharmaceutical Co., Ltd., Ibaraki)

TAS-115, a multi-tyrosine kinase inhibitor, modulates tumor microenvironment and potentiates the antitumor efficacy of anti-PD-1 antibody

Junjiro Yoshida (Institute of Microbial Chemistry, Tokyo)

Mitochondrial complex I inhibitors suppress tumor growth through intra- and extracellular acidification

Sosuke Nakamura (MSD K.K., Tokyo)

Zilovertamab vedotin (MK-2140) for the treatment of non-Hodgkin lymphoma: The phase 1 dose escalation and cohort expansion WAVELINE-001 study of an anti-ROR1 antibody-drug conjugate

Shigehiro Koganemaru (National Cancer Center Hospital East, Chiba)

Relationship between the intratumor pharmacokinetics and antitumor effect of the payload Eribulin in the novel antibody-drug conjugate MORAb-202

Yuki Katayama (Kyoto Prefectural University of Medicine, Kyoto)

EGFR activation promotes adaptive resistance to lorlatinib in ALK-rearranged lung cancer cells

Shun Morino (Cancer Chemotherapy Center, JFCR, Tokyo)

Single cell lineage analysis for tracing drug-tolerant persister cells in patient-derived colorectal cancer cells

Kohei Maruyama (Cancer Chemotherapy Center, JFCR, Tokyo)

Identification of the intrinsic resistance mechanisms to KRAS inhibitors in KRAS mutated colorectal cancer.

Noritaka Tanaka (Kansai Medical University, Osaka)

The collateral effects of KRAS inhibitors on tumor microenvironment

Hiroshi Kotani (Kanazawa University, Ishikawa)

SUMOylation inhibition modulates tumor immunity and activates immune cells

Yusuke Ito (Aichi Cancer Center Research Institute, Aichi)

Optimization of CAR-T cell functions using a gene-editing approach

13:50-14:30

Poster Viewing

14:30-14:40

Break

1 New emerging molecular targets and drugs

Chairpersons: Seiji Yano (Kanazawa Univ., Ishikawa), Shingo Dan (JFCR, Tokyo)

14:40-15:05

Koji Ichikawa (Taiho Pharmaceutical Co., Ltd., Ibaraki)

TAS0612, a potent RSK/AKT/S6K inhibitor targeting cancers with PI3K and MAPK pathway aberrations

15:05-15:45

Victor Moreno (START Madrid-FJD, Madrid, Spain)

Current advances in adoptive cell therapy for solid tumors

15:45-15:55

Discussion

15:55-16:05

Break

2 Targeting KRAS/SOS
Supported by MEXT Grant-in-Aid for Scientific Research on Innovative Areas "Integrated Analysis and Regulation of Cellular Diversity (4904)"

Chairpersons: Ryan Corcoran (MGH Cancer Ctr., Boston, MA, USA),
Hiromichi Ebi (Aichi Cancer Ctr. Res. Inst., Aichi)

16:05-16:45

Ryan Corcoran (MGH Cancer Ctr., Boston, MA, USA)

Overcoming resistance to KRAS inhibition

16:45-17:10

Yoshihisa Kobayashi (National Cancer Ctr. Res. Inst., Tokyo)

Silent mutations associated with oncogenic function of RAS

17:10-17:50

Norbert Kraut (Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria)

Targeting KRAS for cancer care

17:50-18:00

Discussion

December 8

Meet-the-Expert Session

Chairperson: Atsushi Ohtsu (National Cancer Ctr. Hospital East, Chiba)

9:00-9:40

Lillian Siu (Princess Margaret Cancer Ctr., Toronto, Canada)

Rethinking early phase clinical trials in oncology: Dose optimization

9:40-9:50

Discussion

9:50-10:00

Break

3 Targeted protein degradation and PROTACs

Chairpersons: Mikihiko Naito (Univ. Tokyo, Tokyo), Alessio Ciulli (Univ. Dundee, Dundee, UK)

10:00-10:40

Hiroshi Handa (Tokyo Medical Univ., Tokyo)

Identification of thalidomide target CRBN to the development of targeted protein degraders

10:40-11:20

Alessio Ciulli (Univ. Dundee, Dundee, UK)

How PROTAC degraders work: design principles and drug development for challenging cancer targets

11:20-12:00

Debbie Chirnomas (Arvinas, New Haven, CT, USA)

PROTAC® Protein Degraders in the Clinic

12:00-12:10

Discussion

12:10-12:30

Break

Luncheon Seminar

Chairperson: Masanobu Oshima (Kanazawa Univ., Ishikawa)

12:30-13:30

Yasuhiro Yamada (Univ. Tokyo, Tokyo)

The oncogene-dependent resistance to reprogramming unveils cancer therapeutic targets

13:30-13:40

Break

4 Next generation antibody drug therapy

Chairpersons: Shunji Takahashi (JFCR, Tokyo), Ryohei Katayama (JFCR, Tokyo)

13:40-14:05

Soichiro Nishijima (Daiichi Sankyo Co., Ltd., Tokyo)

Clinical development of DXd-ADC franchise

14:05-14:30

Yohei Otake (Eisai Co., Ltd., Tokyo)

MORAb-202 (farletuzumab ecteribulin): from preclinical research to clinical trials and translational analysis

14:30-14:55

Yosuke Togashi (Okayama Univ., Okayama)

TIGIT blockade therapies:Can they overcome resistance to PD-1 blockade therapies?

14:55-15:05

Discussion

Closing Remark

15:05-15:20

Ryan Corcoran (MGH Cancer Ctr., Boston, MA, USA)

Closing remark

Page Top